Wilfredo E De Jesus-Monge, MD, MSc Copyright (c) 2013 All rights reserved. http://works.bepress.com/wilfredodejesusmonge Recent documents in Wilfredo E De Jesus-Monge, MD, MSc en-us Thu, 31 Jan 2013 16:42:05 PST 3600 Involvement of canonical Wnt/β-catenin signaling pathway in pancreatic ductal adenocarcinoma. AACR Annual Meeting, Chicago, IL http://works.bepress.com/wilfredodejesusmonge/37 http://works.bepress.com/wilfredodejesusmonge/37 Mon, 28 May 2012 07:08:33 PDT M. Sano et al. Change in international pancreatic cancer incidence and mortality rates. Center for Clinical & Translational Science Research Retreat, UMass Medical School, Worcester, MA http://works.bepress.com/wilfredodejesusmonge/36 http://works.bepress.com/wilfredodejesusmonge/36 Mon, 28 May 2012 07:03:58 PDT Wilfredo E. De Jesus-Monge et al. Cancer clinical trials: a primer for patients and health care providers http://works.bepress.com/wilfredodejesusmonge/35 http://works.bepress.com/wilfredodejesusmonge/35 Thu, 08 Mar 2012 15:07:49 PST Wilfredo E. De Jesus-Monge et al. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. http://works.bepress.com/wilfredodejesusmonge/34 http://works.bepress.com/wilfredodejesusmonge/34 Thu, 08 Mar 2012 15:00:25 PST M. Rajurkar et al. Descriptive analysis of racial/ethnic differences in subject enrollment for cancer clinical trials. Multidisciplinary Conference in Clinical Research and Summit of Translational Research in Health Disparities, University of Puerto Rico Medical Sciences Campus, San Juan, PR, 2012; Clinical and Translational Research Symposium, Vermont Cancer Center, The University of Vermont and Fletcher Allen Health Care, Burlington, VT, 2011 http://works.bepress.com/wilfredodejesusmonge/33 http://works.bepress.com/wilfredodejesusmonge/33 Mon, 28 Nov 2011 01:06:01 PST Wilfredo E. De Jesus-Monge Female breast cancer in New England: Incidence, mortality, and prevention trends with attention to potential cancer racial/ethnic differences. New England Science Symposium, Harvard Medical School, Boston, MA, 2012. Clinical and Translational Research Symposium, Vermont Cancer Center, The University of Vermont and Fletcher Allen Health Care, Burlington, VT, 2011 http://works.bepress.com/wilfredodejesusmonge/32 http://works.bepress.com/wilfredodejesusmonge/32 Mon, 28 Nov 2011 01:05:18 PST Wilfredo E. De Jesus-Monge et al. Cancer in Worcester, MA: Incidence and mortality trends with a look at racial/ethnic differences. Clinical and Translational Research Symposium, Vermont Cancer Center, The University of Vermont and Fletcher Allen Health Care, Burlington, VT http://works.bepress.com/wilfredodejesusmonge/31 http://works.bepress.com/wilfredodejesusmonge/31 Mon, 28 Nov 2011 01:04:03 PST Wilfredo E. De Jesus-Monge Community engagement approach to address contributors to cancer health disparities in Worcester, MA http://works.bepress.com/wilfredodejesusmonge/30 http://works.bepress.com/wilfredodejesusmonge/30 Tue, 04 Oct 2011 18:17:38 PDT accepted.

]]> Wilfredo E. De Jesus-Monge Community engagement approach to address contributors to cancer health disparities in Worcester, MA. Community Health & Research: Making the Connections, UMass Medical School, Worcester, MA http://works.bepress.com/wilfredodejesusmonge/29 http://works.bepress.com/wilfredodejesusmonge/29 Tue, 04 Oct 2011 18:16:09 PDT Wilfredo E. De Jesus-Monge et al. How to write a proposal for Institutional Review Board (IRB) http://works.bepress.com/wilfredodejesusmonge/25 http://works.bepress.com/wilfredodejesusmonge/25 Sat, 03 Sep 2011 21:27:19 PDT Wilfredo E. De Jesus-Monge Developing a research study plan http://works.bepress.com/wilfredodejesusmonge/24 http://works.bepress.com/wilfredodejesusmonge/24 Sat, 03 Sep 2011 21:25:05 PDT Wilfredo E. De Jesus-Monge [The science fair: your first experience in research] (Spanish) http://works.bepress.com/wilfredodejesusmonge/23 http://works.bepress.com/wilfredodejesusmonge/23 Sat, 03 Sep 2011 21:19:38 PDT [La feria científica escolar es la exhibición de proyectos que utilizan el método científico. La evaluación de los proyectos se basa en cuatro áreas principales. Primero, que la observación o el problema sea original y que resulte en conocimiento nuevo. Segundo, que puedas explicar claramente el tema de tu proyecto, sus limitaciones y qué nuevas preguntas surgieron de tu investigación. Tercero, que la aplicación del método científico haya sido apropiada: especialmente, que la pregunta se derive de una observación o un problema, que la hipótesis busque responder a la pregunta, que el experimento sea adecuado para responder a la pregunta y probar la hipótesis y que haya un adecuado análisis de los resultados. Y cuarto, que demuestres evidencia sólida de los resultados de tu estudio. Un exitoso proyecto de feria científica es original, realizado siguiendo correctamente el método científico y resulta en conocimiento nuevo. A la vez, debe ser presentado de manera clara y organizada. Mientras haces un proyecto de feria científica, ya eres un investigador o una investigadora de verdad]. (Spanish)

Podcast in Spanish.

]]> Wilfredo E. De Jesus-Monge [My experience as a cancer researcher] (Spanish) http://works.bepress.com/wilfredodejesusmonge/22 http://works.bepress.com/wilfredodejesusmonge/22 Sat, 03 Sep 2011 21:16:20 PDT Wilfredo E. De Jesus-Monge Cutaneous manifestations of gastrointestinal diseases http://works.bepress.com/wilfredodejesusmonge/21 http://works.bepress.com/wilfredodejesusmonge/21 Sat, 03 Sep 2011 21:13:00 PDT M. I. Vazquez-Roque et al. Autocrine motility factor in various human melanoma cell lines. 34th American Chemical Society Junior Technical Meeting and 19th PR Interdisciplinary Scientific Meeting, Mayagüez, PR http://works.bepress.com/wilfredodejesusmonge/20 http://works.bepress.com/wilfredodejesusmonge/20 Wed, 28 Apr 2010 15:42:42 PDT Wilfredo E. De Jesus-Monge et al. Proteomics in search of biomarkers for colorectal and pancreatic cancers. National Annual Meeting for CTSA KL2, K12, and K30 Clinical Research Scholars, NIH National Center for Research Resources and Association for Clinical Research Training, Washington, DC http://works.bepress.com/wilfredodejesusmonge/19 http://works.bepress.com/wilfredodejesusmonge/19 Wed, 28 Apr 2010 15:38:35 PDT Wilfredo E. De Jesus-Monge Trends of prevalence of protective and risk factors compared with colorectal cancer incidence in the Hispanic United States population in 2000-2003: an exploratory question. National Hispanic Medical Association Annual Conference, Washington, DC http://works.bepress.com/wilfredodejesusmonge/18 http://works.bepress.com/wilfredodejesusmonge/18 Wed, 28 Apr 2010 15:35:01 PDT Wilfredo E. De Jesus-Monge et al. [Mouse models of human cancer: valuable tools for oncological research] (Spanish) http://works.bepress.com/wilfredodejesusmonge/17 http://works.bepress.com/wilfredodejesusmonge/17 Tue, 27 Apr 2010 15:31:38 PDT [En Puerto Rico, en el 2008, el cáncer fue la segunda causa de muerte, después de las enfermedades del corazón. Además, según datos de 1999-2003, una de cada tres personas en el país será diagnosticada con cáncer durante su vida. Estas cifras alarmantes son un estímulo para continuar la investigación científica de esta terrible enfermedad. Un componente importante de la investigación de cáncer es el ratón. El propósito de este artículo es presentar la valiosa contribución de los modelos de cáncer humano basados en ratones en la investigación oncológica y su relevancia para hallar la prevención y la cura de esta enfermedad]. (Spanish)

]]> Wilfredo E. De Jesus-Monge Age as a deciding factor in the consideration of futility for a medical intervention in patients among Internal Medicine physicians in two practice locations http://works.bepress.com/wilfredodejesusmonge/15 http://works.bepress.com/wilfredodejesusmonge/15 Tue, 26 Jan 2010 08:07:31 PST OBJECTIVES: This study explores physicians' concepts of futility and use of age as a deciding factor in considering medical futility in clinical interventions.

DESIGN: Survey.

SETTING: Five academic hospitals in the United States.

PARTICIPANTS: Participants were 355 internal medicine physicians, including 162 residents, 98 fellows, and 95 attending physicians.

MEASUREMENT: Anonymous questionnaire in which respondents were asked to define futility and to rate patient scenarios as futile or not, unaware that these were pairs of patient scenarios with similar clinical severity and treatment, but different age.

RESULTS: Forty-five percent (n = 159) of physicians used the most accepted definition of futility in the literature: "a therapy that will not benefit the patient in attaining a specific goal." Physicians rated patient scenarios as futile for 58% of elder (> or =65 years) and for 59% of nonelder (<65>years) cases (P = .21). By training level, resident physicians rated more elder cases as futile (60%) than fellow/attending physicians (56%, P = .03). Rating of medical futility did not differ by practice location (59% in Missouri and 59% in Puerto Rico, P = .13).

CONCLUSION: Physicians did not use age as a factor in deciding the futility of a medical intervention. In patient scenarios with comparable clinical severity of illness, medical interventions were similarly rated as futile in elder and nonelder persons. Less-experienced physicians (residents) were more likely to rate elder cases as futile compared with experienced physicians (attending/fellows).

]]> D. M. Cruz-Oliver et al. Complementary and alternative medicine in the treatment of colorectal and pancreatic cancers: promising therapies for the future (Abstract P6) http://works.bepress.com/wilfredodejesusmonge/14 http://works.bepress.com/wilfredodejesusmonge/14 Mon, 25 Jan 2010 10:37:57 PST Purpose of Study: Colorectal and pancreatic cancers were estimated to be the third and fourth leading deadly cancer types, respectively, in both sexes in United States in 2007. As a consequence, complementary and alternative medicine (CAM) has been incorporated into their management programs. The purpose of this study is to discuss some of the CAM modalities, the study of their efficacy, and registered clinical trials in the treatment of colorectal and pancreatic cancers.

Methods Used: A literature search was conducted in MEDLINE. The search terms used were: (complementary OR alternative) AND medicine AND (colorectal OR pancreatic) AND cancer. Articles were considered to satisfy the purpose of this study. The same terms were used to search for registered clinical trials of CAM in colorectal and pancreatic cancers in ClinicalTrials.gov.

Summary of Results: Ukrain is a compound derived from the common weed that has shown increased survival and no progression of tumor in colorectal and pancreatic cancer patients on randomized clinical trials but with many limitations and unreliable methodological quality. Shark cartilage has shown anticancer activity through glycoproteins that has extended life in leukemic mice, inhibition of tumor angiogenesis, and protection against mutagenesis and DNA lesions. However, a clinical trial in patients with incurable colorectal cancer did not show any efficacy. Echinacea reduced cell viability in human colon and pancreatic cancer cell lines. Gamma-linolenic acid has antiproliferative activity against human pancreatic cancer lines. Mistletoe does not significantly influence tumor growth in advanced pancreatic carcinomas. However, its treatment can stabilize the quality of life of patients. The search for registered clinical trials revealed 5 studies: 3 completed, 1 ongoing, and 1 withdrawn (3 for colorectal and 2 for pancreatic cancers).

Conclusions: Physicians must prepare to discuss CAM with cancer patients. Further high quality research with large sample size and controlled environments are necessary to confirm the potential benefits of CAM use in patients with colorectal and pancreatic cancers, as suggested by basic science studies. This study was made possible by grant 2R25RR017589-06 from the NIH NCRR.

]]> Wilfredo E. De Jesus-Monge